Aim: To describe a case of tertiary hyperparathyroidism after long-term phosphate and vitamin D therapy and the retrospective evaluation of parathyroid function in 6 patients with hypophosphatemic osteomalaica. Methods: We evaluated the parathyroid function by measuring iPTH before and during treatment and divided the patients into normal and elevated serum iPTH groups. Results: In the normal serum iPTH group, the 4 patients were all males, whereas the 2 patients in the elevated serum iPTH group were females. Clinical characteristics and biochemical results showed no differences between the two groups. One of the women with an elevated iPTH level (224 pg/ml) had a normal serum calcium level and no evidence of increasing parathyroid uptake by 99mTc-MIBI scan 52 months after treatment. The other woman also had an elevated iPTH level (483 pg/ml) and a normal serum calcium level 56 months after treatment. However, in this latter case both her iPTH (1,447 pg/ml) and serum calcium (11.3 mg/dl) levels were elevated 113 months after treatment, when a 99mTc-MIBI scan showed increased uptake in all four parathyroid glands during early and delayed phases of the scan. Parathyroidectomy was performed after the diagnosis of tertiary hyperparathyroidism was made, and the histological findings showed adenomatous hyperplasia. Conclusions: Our findings indicate that even with vitamin D therapy, long-term phosphate therapy may lead to the development of secondary or tertiary hyperparathyroidism in hypophosphatemic osteomalacia and, therefore, suggest that it is important to carefully monitor the parathyroid function during therapy in those with hypophosphatemic osteomalacia.

Keywords:
Hyperparathyroidism, Hypophosphatemic osteomalacia
1.
Firth RG, Grant CS, Riggs B: Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia: Report of two cases. Am J Med 1985;78:669–673.
2.
Glorieux FH, Marie PJ, Pettifor JM, Dvelin EE: Bone response to phosphate salts, ergocalciferol and calcitriol in familial hypophosphatemic rickets. N Engl J Med 1980;303:1023–1031.
3.
Bettinelli A, Bianchi ML, Mazzucchi E, Gandolini G, Appiani AC: Acute effects of calcitriol and phosphate salts on mineral metabolism in children with hypophosphatemic rickets. J Pediatr 1991;118:372–376.
4.
Amud CD, Glorieux F, Scriver C: Serum parathyroid hormone in X-linked hypophosphatemia. Science 1971;173:845–847.
5.
Hahn TJ, Schrap CR, Halstead LR, Haddad JG, Karl DM, Avioli LV: Parathyroid hormone status and renal responsiveness in familial hypophosphatemic rickets. J Clin Endocrinol Metab 1975;41:926–937.
6.
Scott AR, Ghada E, Edward MB, John DC: Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 1992;75:1514–1518.
7.
Vedere V, Goupille P, Valat JP, Lecomte P: Tertiary hyperparathyroidism induced by the treatment of hypophosphatemic osteomalacia. Ann Endocrinol (Paris) 1996;57:215–218.
8.
Reid IR, Teitelbaum SL, Dusso A, Whyte MP: Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia: Effect of successful tumor resection on mineral homeostasis. Am J Med 1987;83:350–354.
9.
Knudtzon J, Halse J, Monn E, Nesland A, Nordal KP, Paus P, Selp M, Sund S, Sodal G: Autonomous hyperparathyroidism in X-linked hypophosphatemia. Clin Endocrinol (Oxf) 1995;42:199–203.
10.
Narvaez J, Rodriguez-Moreno J, Moragues C, Campoy E, Clavaguera T, Roig-Escofet D: Tertiary hyperparathyroidism after long-term phosphate supplementation in adult-onset hypophosphataemic osteomalacia. Br J Rheumatol 1996;35:598–600.
11.
Henneman PH, Dempsey EF, Carroll EL, Henneman DH: Acquired vitamin D resistant osteomalacia: A new variety characterized by hypercalcemia, low serum bicarbonate, and hyperglycinuria. Metabolism 1962;11:103–116.
12.
Edelson G, Shih MS, Parfitt AM: A unique case of adult hypophosphate osteomalacia. Bone 1993;14:707–710.
13.
Walton RJ, Bijvoet OL: Nomogram for derivation of renal threshold phosphate concentration. Lancet 1975;ii:309–310.
14.
Balsan S, Tieder M: Linear growth in patients with hypophosphatemic vitamin D-resistant rickets: Influence of treatment regimen and parental height. J Pediatr 1990;116:365–371.
15.
Ghan JC, Lovinger RD, Mamunes P: Renal hypophosphatemic rickets: Growth acceleration after long-term treatment with 1,25-dihydroxyvitamin D3. Pediatrics 1980;66:445–454.
16.
Hebert LA, Lemann J Jr, Petersen JR, Lennon EJ: Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 1966;45:1886–1894.
17.
Alon U, Chan JC: Effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on tubular handling of phosphate in hypophosphatemic rickets. J Clin Endocrinol Metab 1994;58:671–674.
18.
Schapira D, Ben Izhak O, Nachtigal A, Burstein A, Shalom RB, Shagrawi I, Best LA: Tumor-induced osteomalacia. Semin Arthritis Rheum 1995;25:35–46.
19.
Harvey JN, Gray C, Belchetz PE: Oncogenous osteomalacia and malignancy. Clin Endocrinol (Oxf) 1992;37:379–382.
20.
Huang QL, Feig DS, Blackstein ME: Development of tertiary hyperparathyroidism after phosphate supplementation in oncogenic osteomalacia. J Endocrinol Invest 2000;23:263–267.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.